Skip to main content
Clinical Trials/NCT01963585
NCT01963585
Completed
Not Applicable

Evaluating the Capacity of High-sensitivity Serum CRP Levels to Predict Bronchial Hyper Responsiveness in School Age Children

Rambam Health Care Campus0 sites131 target enrollmentJuly 2011

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Hyperreactive Airway
Sponsor
Rambam Health Care Campus
Enrollment
131
Primary Endpoint
HIgh sensitive C-reactive protein
Status
Completed
Last Updated
12 years ago

Overview

Brief Summary

Background:

Bronchial hyper responsiveness (BHR) assessed by methacholine challenge test (MCT) may aid in the diagnosis of asthma, while negative MCT can help to exclude the diagnosis. Laboratory measures that predict the results of MCT are expected to reduce the number of procedures. The possible capacity of High sensitive C-reactive protein (hs-CRP), a marker of systemic inflammation, to predict negative or positive MCT in children has not been evaluated.

Aim: to evaluate the capacity of hs-CRP to predict positive or negative MCT in school aged children and to compare it with markers of airway inflammation: Fractional exhaled Nitric Oxide (FeNO) and markers of allergic sensitization (IgE and peripheral blood eosinophils).

Design: Prospective study evaluating these parameters in patients with positive and negative MCT.

Participant selection: The study population included subjects (age range 6 to 18 years) referred for Methacholine Challenge Test (MCT)

Sample size: 130 participants in the two groups. Intervention: Each subject will undergo evaluation including a respiratory questionnaire, methacholine challenge test with determination of PC20(the provocative concentration that reduced FEV1 by 20% from baseline), exhaled nitric oxide (eNO). Venous blood will be analyzed for complete blood count + eosinophils, IGE levels, hs-CRP. All measurements will be evaluated in a single 3 hour visit, with no follow up study visits.

Primary end point: hs-CRP levels as add on tool to predict negative or positive MCT in children Secondary outcome parameters: All other parameters are the secondary end points.

Registry
clinicaltrials.gov
Start Date
July 2011
End Date
October 2013
Last Updated
12 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age range 6 to 18 years
  • Patient referred for Methacholine Challenge Test (MCT)

Exclusion Criteria

  • Base line FEV1(forced expiratory volume in the first second) \< 65%
  • The presence of other systemic or lung disease
  • Anti-inflammatory drugs
  • Upper respiratory tract infection in the last month

Outcomes

Primary Outcomes

HIgh sensitive C-reactive protein

Time Frame: participants will be followed for the duration of hospital visit, an average of 3 hours

in peripheral Blood count

Secondary Outcomes

  • complete blood count(participants will be followed for the duration of hospital visit, an average of 3 hours)
  • IgE(participants will be followed for the duration of hospital visit, an average of 3 hours)
  • Metacholine Challenge Test(participants will be followed for the duration of hospital visit, an average of 3 hours)
  • Fractional Exhaled NO(participants will be followed for the duration of hospital visit, an average of 3 hours)
  • body mass index(participants will be followed for the duration of hospital visit, an average of 3 hours)

Similar Trials